ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--April 18, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the following investor conferences:
- The 7th Annual Fortis Bank Biotechnology Conference on Wednesday, April 25, 2007 at 10:30 a.m. Western European Time at the Four Seasons Hotel London, in London, England.
- The Deutsche Bank 32nd Annual Healthcare Conference on Wednesday, May 2, 2007 at 9:45 a.m. Eastern Time at the Renaissance Mayflower Hotel in Washington, D.C.
- The Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference on Monday, May 14, 2007 at 10:05 a.m. Central European Time at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
Live webcasts of these presentations will be accessible on the company's website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website for two weeks following the presentation.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA currently has five clinical programs as well as a portfolio of preclinical and discovery assets directed at large unmet medical needs, including schizophrenia, Parkinson's disease psychosis, sleep maintenance insomnia, and neuropathic pain. All of the drug candidates in ACADIA's product pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA's corporate headquarters is located in San Diego, California and it maintains research and development operations in both San Diego and Malmo, Sweden.
CONTACT: ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and Chief Financial Officer
SOURCE: ACADIA Pharmaceuticals Inc.